DrugPatentWatch Database Preview

Details for Patent: 10,004,746

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,004,746 protect, and when does it expire?

Patent 10,004,746 protects IMBRUVICA and is included in two NDAs.

This patent has forty-three patent family members in seventeen countries.

Summary for Patent: 10,004,746

Title:	Use of inhibitors of Bruton's tyrosine kinase (Btk)
Abstract:	Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
Inventor(s):	Buggy; Joseph J. (Mountain View, CA), Elias; Laurence (Berkeley, CA), Fyfe; Gwen (San Francisco, CA), Hedrick; Eric (Summit, NJ), Loury; David J. (Incline Village, NV), Mody; Tarak D. (Sunnyvale, CA)
Assignee:	Pharmacyclics LLC (Sunnyvale, CA)
Application Number:	15/659,803
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,004,746
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,004,746

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-001	Nov 13, 2013		RX	Yes	Yes						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION

International Family Members for US Patent 10,004,746

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011261185
Australia	2015275321
Australia	2018204179
Australia	2020202752
Brazil	112012030625